Pulmongene
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A gene therapy biotech targeting rare lung diseases and oncology with viral vector-based platforms.
RespiratoryOncologyGenetic Disorders
Technology Platform
Engineers novel viral vectors, particularly AAV, for targeted delivery of therapeutic genes to lung tissue and tumors.
Opportunities
Addressing significant unmet need in genetic respiratory diseases and leveraging vector technology for high-value oncology applications.
Risk Factors
Faces substantial scientific, manufacturing, and regulatory risks inherent to gene therapy, particularly for new vector designs.
Competitive Landscape
Operates in the nascent Chinese gene therapy space for lung disease, with broader competition in oncology from numerous biotechs.